Showing 4221-4230 of 8202 results for "".
- EULAR News: Tremyfa Data Shows Sustained Improvements in PsAhttps://practicaldermatology.com/news/eular-news-tremyfa-data-showing-sustained-improvements-in-psa/2461755/Tremfya (guselkumab) provides sustainable improvements in all minimal disease activity (MDA) domains through week 48 in adults with active psoriatic arthritis (PsA) who previously had an inadequate response to one to two tumor necrosis factor inhibitors (TNFi-IR), according to new data
- Sun Pharma, Philogen Enter Into an Exclusive Distribution, License, and Supply Agreement for Nidlegy in Europe, Australia, and New Zealandhttps://practicaldermatology.com/news/sun-pharma-philogen-enter-into-an-exclusive-distribution-license-and-supply-agreement-for-nidlegy-in-europe-australia-and-new-zealand/2461752/Sun Pharmaceutical Industries has entered into a licensing agreement for commercializing Philogen’s Nidlegy (Daromun) in the territories of Europe, Australia and New Zealand. Nidlegy, currently in Phase III clinical trials, is a new anti-cancer biopharmaceutical which is bei
- Nivea's Skin Out Loud Series Tackles Skin Diversityhttps://practicaldermatology.com/news/niveas-skin-out-loud-series-tackles-skin-diversity/2461751/Nivea is rolling out a five-episode "Skin Out Loud" series. The series features a diverse cast of hosts including TV Host Milka Loff Fernandes, Brigiding from RuPaul's Drag Race Philippines, South African skinfluencer Zithobe
- DermBiont's 0.8% SM-030 Topical Gel Fades Solar Lentigos, Normalizes Pigmentation in Phase 2 Studyhttps://practicaldermatology.com/news/dermbionts-08-sm-030-topical-gel-fades-solar-lentigos-normalizes-pigmentation-in-phase-2-study/2461748/DermBiont’s 0.8% SM-030 gel performed well in a Phase 2 trial treating solar lentigos and normalizing pigmentation of the skin, the Company reports. SM-030 is a first-in-class selective and potent topical PKCβ inhibitor intended to reduce the production of epidermal mela
- Lumohs, George Tiemann and Company Join Forces to Distribute Lumohs’ Illuminating Devicehttps://practicaldermatology.com/news/lumohs-george-tiemann-and-company-join-forces-to-distribute-lumohs-illuminating-device/2461747/Nano Surgical is partnering with George Tiemann and Company, to bring Lumohs’ illuminating device to dermatology market. Lumohs is a patented, reusable scalpel handle that provides integrated shadowless illumination of the surgical site. With no light obstructions between th
- Epigenetic Mechanisms Activated by GHK-Cu Increase Skin Collagen Densityhttps://practicaldermatology.com/news/epigenetic-mechanisms-activated-by-ghk-cu-increase-skin-collagen-density/2461744/Epigenetic mechanisms activated by GHK-Cu may increase skin collagen density, new research suggests. The naturally occurring peptide GHK-Cu (GHK from glycyl-L-histidyl-L-lysine bound to a copper ion), which affects
- Melanoma Metastasis Discovery: Skin Cancer Rewires Energy Systems to Spreadhttps://practicaldermatology.com/news/melanoma-metastasis-discovery-skin-cancer-rewires-energy-systems-to-spread/2461743/Melanoma skin cancer cells may rewire their internal power systems to drive their spread to other parts of the body, a new study suggests. The research, led by investigators at Barts Cancer Institute, Queen Mary Unive
- PsO Pipeline Update: First Cohort of Patients Dosed with LNK01004 in Phase Ib Studyhttps://practicaldermatology.com/news/pso-pipeline-update-first-cohort-of-patients-dosed-with-lnk01004-in-phase-ib-study/2461742/The first cohort of psoriatic patients have been dosed in a Phase Ib clinical trial of Lynk Pharmaceuticals Co., Ltd.’s LNK01004. The trial was designed to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of LNK01004 ointment in Chinese p
- Almirall, CRG Partner to Develop Novel Preclinical Models for NMSChttps://practicaldermatology.com/news/almirall-crg-partner-to-develop-novel-preclinical-models-for-nmsc/2461741/Almirall and the Centre for Genomic Regulation (CRG) are joining forces to develop and characterize novel preclinical models that will help identify new treatments for non-melanoma skin cancer (NMSC). This partnership, led by Almirall's investigators Dr
- It's Going to Be a Scorcher: Experts Predict Extreme UV Index Ratings This Memorial Dayhttps://practicaldermatology.com/news/its-going-to-be-a-scorcher-experts-predict-extreme-uv-index-ratings-this-memorial-day/2461739/A dozen U.S. cities are expected to have extreme ultraviolet (UV) index ratings (10+) this Memorial Day and throughout the summer, according to data from the